Search clinical trials for: LY3039478 new formulation

Total 2637 results

Eli Lilly and Company

Completed

A Study of LY3039478 in Healthy Participants

Healthy

United States
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
GlaxoSmithKline

Completed

A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.

Substance Dependence

United Kingdom
The Netherlands Cancer Institute

Completed

Study With Improved Solubility Pazopanib

Pharmacokinetics of Pazopanib

Netherlands
Eli Lilly and Company

Completed

Study of LY3039478 in Healthy Participants

Healthy

United Kingdom
Takeda

Completed

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

Healthy

United States
Eli Lilly and Company

Completed

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumor

Japan
GlaxoSmithKline

Completed

Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers

Herpes Labialis

Japan
ESM Technologies, LLC

Completed

Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders

Osteoarthritis | Fibromyalgia

United States
Boehringer Ingelheim

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Healthy
Takeda

Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Hypothyroidism

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

HIV Infections
Derming SRL

Completed

Evaluation of Tolerance and Trichological Efficacy of a Food Supplement

Telogen Effluvium
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
Embera NeuroTherapeutics, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

Cocaine Use Disorder

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Boehringer Ingelheim

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Healthy
TaiGen Biotechnology Co., Ltd.

Completed

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy
ViiV Healthcare

Completed

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
GlaxoSmithKline

Completed

Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants

Hypertension, Pulmonary

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Measles | Rubella | Mumps | Varicella

Taiwan, Singapore
Hillel Yaffe Medical Center

Unknown

Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.

Skin Abnormality

Israel
Bayer

Completed

Moisturizing Effect of Two Dexpanthenol Formulations

Skin Abnormalities

France
Boehringer Ingelheim

Completed

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Healthy
Bayer

Completed

Efficacy of Dexpanthenol in Thermic Erythema

Erythema

France
Alcon Research

Completed

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Ocular Hypertension | Glaucoma
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
EMD Serono

Completed

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, Sweden
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
Universitätsklinikum Hamburg-Eppendorf

Unknown

Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)

Sepsis

Germany
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
Janssen Sciences Ireland UC

Completed

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Healthy

United Kingdom
Allergan

Completed

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Dry Eye Disease (DED)

United States
Peking University First Hospital

Recruiting

The Best Timing of Delivery in Women With GDM Study

Gestational Diabetes | Induction of Labor Affected Fetus / Newborn

China
GlaxoSmithKline

Completed

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Multiple Sclerosis

Poland, Germany, Czechia
Pfizer

Completed

Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers

Healthy

Singapore
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
GlaxoSmithKline

Completed

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Systemic Lupus Erythematosus

United States
GlaxoSmithKline

Completed

Bioequivalence and Food Effect Study in Healthy Volunteers

Sleep Initiation and Maintenance Disorders

Italy
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
ViiV Healthcare

Recruiting

A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants

HIV Infections

United Kingdom
Boehringer Ingelheim

Completed

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Healthy
Pepperdine University
University of California, Los Angeles

Completed

Evaluating New Mexico's Recidivism Reduction Program (RRP)

Behavior

United States

3

Subscribe